This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Investigations of Nucleoside *H*-Phosphonamidate in the Design of Nucleotide Prodrug

D. Egron^a; J. -L. Imbach^a; G. Gosselin^a; A. -M. Aubertin^b; C. Périgaud^{ac}

^a Université Montpellier II, Montpellier, France ^b Laboratoire de Virologie de la Faculté de Médecine, Université L. Pasteur, Strasbourg, France ^c Laboratoire de Chimie Organique Biomoléculaire de Synthese, Université Montpellier II, Place E. Bataillon, Montpellier Cedex 05, France

Online publication date: 09 August 2003

To cite this Article Egron, D. , Imbach, J. -L. , Gosselin, G. , Aubertin, A. -M. and Périgaud, C.(2003) 'Investigations of Nucleoside H-Phosphonamidate in the Design of Nucleotide Prodrug', Nucleosides, Nucleotides and Nucleic Acids, 22: 5, 895-897

To link to this Article: DOI: 10.1081/NCN-120022680 URL: http://dx.doi.org/10.1081/NCN-120022680

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS Vol. 22, Nos. 5–8, pp. 895–897, 2003

Investigations of Nucleoside *H*-Phosphonamidate in the Design of Nucleotide Prodrug

D. Egron, J.-L. Imbach, G. Gosselin, A.-M. Aubertin, and C. Périgaud,*

¹Université Montpellier II, UMR 5625 CNRS, Montpellier, France ²Laboratoire de Virologie de la Faculté de Médecine, Université L. Pasteur, Unité 74 I.N.S.E.R.M, Strasbourg, France

ABSTRACT

The synthesis, anti-HIV activity and stability studies of a *H*-phosphonamidate derivative of 3'-azido-2',3'-dideoxythymidine (AZT) incorporating a *N*,*N*-diisopropylamino residue as first model of alkylamino group are reported. The results demonstrate that such phosphorylated structure exerts its biological effects via chemical hydrolysis into the corresponding *H*-phosphonate, precursor of the parent nucleoside.

Key Words: Prodrug; Mononucleotide; Bioconversion.

895



^{*}Correspondence: C. Périgaud, Laboratoire de Chimie Organique Biomoléculaire de Synthese, Université Montpellier II, UMR 5625 CNRS, CC008, Place E. Bataillon, F-34095 Montpellier Cedex 05, France; Fax: +33 4 6704 2029; E-mail: perigaud@univ-montp2.fr.

896 Egron et al.

Nu = nucleoside analogue

Figure 1.

The use of structurally phosphate modified nucleotides is one of the strategies envisaged to improve the therapeutic efficiency of nucleoside analogues. Such entities would be expected to act as mononucleotide prodrugs (pronucleotides) leading to the delivery of the corresponding mononucleotides inside infected cells.^[1] This approach has been particularly illustrated by the study of nucleoside *H*-phosphonate,^[2] fluorophosphate^[3] or phosphoramidate^[4] monoester derivatives (Fig. 1).

As part of our ongoing research on this topic, we decided to evaluate the potentialities of new series of H-phosphonate derivatives having a nitrogen atom linked to the phosphorus center, i.e., nucleoside H-phosphonamidate (Fig. 1). Using AZT as nucleoside model, the synthesis of the H-phosphonamidate derivative incorporating a N,N-diisopropylamino residue was performed by coupling successively AZT with bis(N,N-diisopropylamino) chlorophosphine, and in situ hydrolysis in presence of tetrazole and water (Sch. 1).

In two human T₄-lymphoblastoid cell lines, the studied *H*-phosphonamidate derivative displayed an anti-HIV activity comparable to AZT, with an effective concentration about submicromolar range. In contrast, no antiretroviral activity was observed in thymidine kinase-deficient CEM cells indicating the unsuccessful intracellular release of the corresponding 5′-mononucleotide. This point was corroborated by stability studies in several media which showed that the *H*-phosphonamidate structure was hydrolysed to the corresponding *H*-phosphonate derivative, precursor of the parent nucleoside.^[2]

Scheme 1.

Downloaded At: 11:07 26 January 2011

REFERENCES

- 1. Périgaud, C.; Gosselin, G.; Imbach, J.-L. Anti-HIV phosphotriester pronucleotides: Basis for the rational design of biolabile phosphate protecting groups. In *Biomedical Chemistry. Applying Chemical Principles to the Understanding and Treatment of Disease*; John Wiley & Sons Inc.: New York, 2000; 115–141.
- 2. Gosselin, G.; Périgaud, C.; Lefebvre, I.; Pompon, A.; Aubertin, A.-M.; Kirn, A.; Szabo, T.; Stawinski, J.; Imbach, J.-L. 5'-Hydrogenphosphonates of anti-HIV nucleoside analogues revisited: Controversial mode of action. Antiviral Res. 1993, 22, 143–153.
- 3. Egron, D.; Arzumanov, A.A.; Dyatkina, N.B.; Aubertin, A.-M.; Imbach, J.-L.; Gosselin, G.; Krayevsky, A.; Périgaud, C. Synthesis, anti-HIV, and stability studies of 5'-phosphorofluoridate derivatives of AZT. Bioorg. Chem. **2001**, *29*, 333–344.
- 4. Wagner, C.R.; Iyer, V.V; McIntee, E.J. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. **2000**, *20*, 417–451.